Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Verdict

Headline takes no side. We score RHEL +0.60 across three claims.

Our read: bullish.

RHEL score

+0.60

−1 bearish0bullish +1

More positive than 76% of ticker scores this week

Price reaction

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

Analysis by

What matters in this story